Mezigdomide Plus Dexamethasone Generates Encouraging Responses in R/R Myeloma
September 4th 2023Patients with heavily pretreated relapsed/refractory multiple myeloma, including those with lenalidomide and pomalidomide-refractory disease, showed encouraging responses with mezigdomide plus dexamethasone.
Adding Pembrolizumab to COPDAC-28 Consolidation May Augment Responses in Classical Hodgkin Lymphoma
September 4th 2023Patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy may benefit from the addition of pembrolizumab to COPDAC-28 consolidation.
Developing a High-Risk Cancer Prevention and Wellness Program to Meet Community Needs
August 28th 2023The program’s initiative aims to identify those at increased risk for cancer through assessment and testing and then formulate a personalized evidence-based cancer surveillance or screening plan.
ASCO/SIO Panel Recommends Mindfulness-Based Interventions to Manage Anxiety During Cancer Treatment
August 21st 2023Experts with the Society for Integrative Oncology and the American Society of Clinical Oncology recommend mindfulness-based interventions to help patients with cancer manage anxiety and depression symptoms.
Tucatinib/Letrozole/Palbociclib Combo Shows Initial Efficacy in HR+/HER2+ Metastatic Breast Cancer
August 19th 2023At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.